Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Kidney Neoplasms 1KRAS G12V Mutant Advanced Epithelial Cancers 1Hodgkin Disease 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 193fludarabine phosphate 123Peripheral Blood Stem Cell Transplantation 107Etoposide 106Mycophenolic Acid 95Filgrastim 92Doxorubicin 85Whole-Body Irradiation 84Tacrolimus 81Brentuximab Vedotin 80Melphalan 78Busulfan 75Radiotherapy 74fludarabine 68Cyclosporine 67Vinblastine 65Rituximab 60Dacarbazine 56Granulocyte Colony-Stimulating Factor 53Gemcitabine 52Antilymphocyte Serum 51Bleomycin 50Nivolumab 47Methotrexate 47Vincristine 46Prednisone 45Cytarabine 44pembrolizumab 36Carmustine 36Bendamustine Hydrochloride 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × Insulin Infusion Systems × Clear all
NCT06090864 2025-10-20

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
31 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡